Naxitamab, also known as naxitamab-gqgk and development code hu3F8, is a humanized monoclonal antibody that targets the disialoganglioside GD2. It is an oncology-focused biological therapeutic used in the treatment of certain high-risk neuroblastoma cases.
Naxitamab is a complex protein-based biological molecule rather than a conventional small-molecule API. Its quality evaluation therefore involves antibody identity, purity, aggregation, charge variants, glycosylation and biological activity.
Naxitamab is a specialized biopharmaceutical API relevant to antibody-drug development and targeted oncology applications. The material requires appropriate biological manufacturing, purification and analytical characterization.
CAS Number: Not established / not routinely applicable
Molecular Formula: Not applicable as a conventional small molecule
Molecular Weight: Approximately 150 kDa
Molecule Type: Humanized monoclonal antibody
Antibody Isotype: IgG1
Target: GD2 (disialoganglioside)
Drug Class: Monoclonal Antibody
Therapeutic Area: Oncology
Development Code: hu3F8
Naxitamab binds to GD2, a ganglioside expressed at high levels on neuroblastoma cells and certain other tumors.
Its activity involves:
By binding GD2 on tumor cells, naxitamab can recruit immune effector mechanisms that contribute to destruction of targeted malignant cells.
Naxitamab is relevant to:
Naxitamab is particularly associated with high-risk neuroblastoma. The antibody targets GD2, a cell-surface antigen highly expressed by neuroblastoma cells, making it an important target for antibody-based cancer therapy.
Naxitamab is a protein-based monoclonal antibody. Its physical properties depend on the formulation and manufacturing process. Biological preparations are typically evaluated for appearance, concentration, aggregation, purity and other protein-quality attributes rather than conventional small-molecule characteristics such as melting point.
A controlled monoclonal-antibody manufacturing process may generally include:
Typical Naxitamab biological-product characterization may include:
Store Naxitamab according to the validated storage conditions of the applicable formulation and approved product specification. Temperature control, light protection and freeze-thaw limitations should be established from validated stability data.
Naxitamab is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |